Study of how ontunisertib is processed in healthy men
Part of Digestive system clinical trials.
This study tests how a new drug, ontunisertib, is processed by the body and eliminated. Healthy men will take a single dose with a tiny radioactive tracer so researchers can track the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man between 30 and 65 years old.
- You must be in good general health, with no significant medical problems.
- Your body mass index (BMI) must be between 18.0 and 29.9.
- You must agree to use effective contraception for 93 days after the last dose.
- You cannot have any history of serious stomach, liver, kidney, or mental health issues.
- You cannot have had significant radiation exposure in the past year or five years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called ontunisertib versus a placebo in people with Crohn's disease that has caused narrowing (strictures) in the small intestine. It aims to see if the drug can help without needing surgery or other procedures.
This early-phase trial tests a new radioactive tracer to see how it binds in healthy people and in patients with fatty liver disease (MASH), Crohn's disease, or primary sclerosing cholangitis. The goal is to learn if the tracer can help detect or monitor these conditions.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
This trial is testing a new drug called SCB0020160 in healthy adult men to see how safe it is and how the body processes it. You take the drug by mouth once or several times.
This Phase 1 trial tests a new drug called LMT503 in adults to learn its safety, tolerability, and how the body handles it. If you qualify, you may receive the study medicine in a controlled research setting with regular checkups and blood/heart monitoring.
This is an early-stage study testing a new drug called TL-003 to see if it's safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with ulcerative colitis (an inflammatory bowel disease) to understand if it might help reduce inflammation.
Hear when a new Fibrostenotic Crohn's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.